Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Boston)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity.
Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J.
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, November 7, 2015, Abstract B115.